• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Recent advances in artificial intelligence for pancreatic ductal adenocarcinoma

    2021-12-03 06:15:24HiromitsuHayashiNorioUemuraKazukiMatsumuraLiuZhaoHirokiSatoYutaShiraishiYoichiYamashitaHideoBaba
    World Journal of Gastroenterology 2021年43期

    Hiromitsu Hayashi, Norio Uemura, Kazuki Matsumura, Liu Zhao, Hiroki Sato, Yuta Shiraishi, Yo-ichi Yamashita, Hideo Baba

    Abstract Pancreatic ductal adenocarcinoma (PDAC) remains the most lethal type of cancer.The 5 -year survival rate for patients with early-stage diagnosis can be as high as 20 %, suggesting that early diagnosis plays a pivotal role in the prognostic improvement of PDAC cases. In the medical field, the broad availability of biomedical data has led to the advent of the “big data” era. To overcome this deadly disease, how to fully exploit big data is a new challenge in the era of precision medicine. Artificial intelligence (AI) is the ability of a machine to learn and display intelligence to solve problems. AI can help to transform big data into clinically actionable insights more efficiently, reduce inevitable errors to improve diagnostic accuracy, and make real-time predictions. AI-based omics analyses will become the next alterative approach to overcome this poor-prognostic disease by discovering biomarkers for early detection, providing molecular/genomic subtyping, offering treatment guidance, and predicting recurrence and survival.Advances in AI may therefore improve PDAC survival outcomes in the near future. The present review mainly focuses on recent advances of AI in PDAC for clinicians. We believe that breakthroughs will soon emerge to fight this deadly disease using AI-navigated precision medicine.

    Key Words: Pancreatic cancer; Pancreatic ductal adenocarcinoma; Artificial intelligence;Machine learning; Precision medicine

    INTRODUCTION

    Pancreatic ductal adenocarcinoma (PDAC) stands the most life-threatenning type of cancer[1]. The recent 5 -year survival rate for PDAC in all stages is 8 .5 % according to American Cancer Society statistics 2017 . In patients with early-stage diagnosis, the 5 -year survival rate for can be as high as 20 %. During the past ten years, median overall survival (OS) has improved from 22 .1 mo to 35 mo in resectable PDAC, considerably owing to improvements in adjuvant therapies[2 -5]. These findings suggest that early diagnosis plays a pivotal role in the prognostic improvement of PDAC cases.Furthermore, the high recurrence rate, even in patients who have undergone curative resection, and chemoresistance to the current systemic chemotherapies (FOLFIRINOX:5 -fluorouracil, folinic acid, irinotecan, and oxaliplatin; and GnP: Gemcitabine plus nabpaclitaxel)[6 ,7] are major issues. Based on recent advances in genetic analysis, PDACs have been divided into several molecular subtypes[8 -11], which is a prelude of precision medicine. Genetic and molecular profiling researches have revealed that up to 25 % (range 12 %-25 %) of PDACs maintained actionable molecular alterations.Actually, matching to relevant molecular-specific treatments improves the OS compared to that of those without actionable mutations or those who do not receive molecular-specific therapy[12]. The comprehensive biomedical data has led to the dawn of the “big data” era in the medical field[13].

    To overcome this deadly disease, how to well utilize big data is a next step for physicians and researchers physicians in the era of precision medicine. The main issue for physicians has shifted from gathering data to competently analyzing it. Artificial intelligence (AI) is the ability of a machine to learn and display intelligence to solve problems (Figure 1 )[14]. An artificial neural network (ANN) can imitate the human neural meridian system. It is divided into three parts: Input layer, hidden layer, and output layer. “Deep learning” refers to an ANN with multiple hidden layers. Machine learning helps researchers spend less time on data processing. The processess for employing machine learning generally contain the following: Gathering the basic data,separating the data into an experimental group and a verification group, buildinging a screening and processing model, inputting the experimental group data into the model, accounting the output results, and confirming the model’s workability using the verification group. The verification group can be employed to examine the sensitivity and specificity of the experimental group, while the experimental group can fabricate more intelligent model. An overview of types in AI is provided in the Supplementary material. Chenet al[15] developed a survival prediction model of non-small cell lung cancer patients through the use of ANN. AI has also been applied to tackle and manage the recent coronavirus disease 2019 crisis in many areas, including screening, diagnosis, severity stratification, mortality prediction, and epidemiology controls[16].

    In the age of precision medicine, AI can support to convert big data into clinically actionable perception more conveniently, reduce the inevitable errors to improve diagnostic accuracy, and make real-time predictions[17 ,18]. Due to latest breakthroughs, the demand of AI in cancer treatment has been swiftly increasing, including for PDACs[19 -21]. Recent studies have demonstrated considerable potential for AI application in PDAC care (Table 1 ). Advances in AI for PDACs may thus be thealternative stream to improve survival outcomes for this deadly disease. The present review mainly focuses on recent advances of AI in PDAC care for clinicians.

    Table 1 Comprehensive list of artificial intelligence-based investigations in pancreatic ductal adenocarcinoma

    Molecular subtype Kaissis et al[68], 2020 CT Random forest 84920 .93 Tumor subtype (QM vs non-QM)Kaissis et al[67], 2019 MRI Gradient boosting decision tree 90920 .93 Molecular subtype (KRT81 positive vs negative)Microsatellite instability status Li et al[19], 2020 PreMSIm (15 -gene signature)k-NN 859795 AI: Artificial intelligence; PDAC: Pancreatic ductal adenocarcinoma; NA: Not available; ROC-AUC: Area under the receiver operating characteristic curve;ICD-9 : International Classification of Diseases 9 th Revision; ANN: Artificial neural network; CT: Computed tomography; DCNN: Deep convolutional neural network; EUS: Endoscopic ultrasound; NN: Neural network; CA19 -9 : Carbohydrate antigen 19 -9 ; IPA: Index of prediction accuracy; MRI: Magnetic resonance imaging; QM: Quasi-mesenchymal; PSO: Particle swarm optimization; NCA: Neighborhood components analysis; k-NN: k-Nearest neighbor.

    Figure 1 Differences among artificial intelligence, machine learning, neural network, and deep learning.

    PDAC RISK PREDICTION BY AI

    The radiographic traits of unoperability and the appearance of symptoms of PDAC occur concurrently[22]. At the time of diagnosis, only a small part of patients (< 15 %)have surgically resectable state[22]. In addition, identification of individuals at high risk for PDAC or with early stage is hard due to the absence of trusty screening tools,the lack of clinically relevant biomarkers, and low prevalence[22]. No established screening strategy has been introduced for sporadic PDAC. It is estimated that symptoms manifest about 6 mo after PDAC becomes unresectable[22]. Identifying individuals at high risk but asymptomatic is crucial for finding PDAC while it is still resectable.

    Approximately 50 % of all patients with PDAC develop diabetes mellitus prior to their diagnosis[23 ,24]. Screening patients with new-onset diabetes may enable earlier diagnosis of PDAC. In pre-diabetic and new-onset diabetic patients, an AI-based prediction model of PDAC risk has been developed[25 ,26]. In a pre-diabetic study, 245 of 138232 patients with impaired fasting glucose were thereafter diagnosed as having PDAC within 3 years of impaired fasting glucose detection. The AI (logistic regression model)-based prediction model consisted of age, body mass index, PPIs, total cholesterol, low-density lipoprotein, alanine transaminase, and alkaline phosphatase[25]. This model achieved an area under the curve (AUC) of 0 .71 . Furthermore, by analyzing 109 ,385 new-onset diabetic patients including 390 PDAC cases, a multivariable prediction (logistic regression) model that included age, smoking, body mass index, change in body mass index, usage of proton pump inhibitors and antidiabetic medications (insulin, oral hypoglycemic except metformin, and metformin), as well as levels of hemoglobin, hemoglobin A1 C, creatinine, cholesterol, and alkaline phosphatase, was established (AUC, 0 .82 )[26]. Among these diabetic patients, 390 (0 .4 %) were diagnosed with PDAC within 3 years. If the predicted risk threshold for definitive PDAC screening was set at 1 % over 3 years, only 6 .19 % of the new-onset diabetes cases would undergo definitive screening, which could identify PDAC cases with 94 .0 % specificity, 44 .7 % sensitivity, and a positive predictive value of 2 .6 %[26].

    Caiet al[27] established a PDAC risk prediction model by analyzing 138 chronic pancreatitis patients with focal mass lesions. A scoring method based logistic regression was employed to build the prediction model, which included five variables:sex, mass number, mass location, bilirubin, and carbohydrate antigen 19 -9 (CA19 -9 )(AUC, 0 .72 ). Hsieh et al[28] predicted PDAC in patients with type 2 diabetes using ICD-9 code data by logistic regression and ANN models. The AUCs achieved by these models were 0 .72 [27] and 0 .73 [28], respectively.

    Appelbaumet al[29] used a logistic regression model and developed a prediction model of PDAC using electronic health record data. A total of 18 risk factors (i.e., age,gender, race, abdominal pain, angina pectoris, asthma, atherosclerotic heart disease,calculus gallbladder, chest pain, chronic pancreatitis, coronary heart disease, diabetes mellitus, emphysema, essential hypertension, family history pancreatic cancer,jaundice, stroke, and ulcer) were used to weigh the risk factors, and their prediction model displayed an AUC of 0 .71 . Their risk model based on patients’ prior diagnoses derived from electronic health record data would predict PDAC 6 -12 mo before an eventual diagnosis date. Such a risk score could be employed as an initial screening prior to additional biomarkers or genetic testing, to pick out individuals from the general population for closer surveillance.

    Muhammadet al[30] used the ANN model to focus on the early prediction and stratification of PDAC risk based on personal health data (800114 answers in the National Health Interview Survey and Pancreatic, Lung, Colorectal, and Ovarian cancer datasets, including 898 cases diagnosed with pancreatic cancer) before symptoms appear. The prediction model using 18 personal health features produced a specificity of 80 .7 %, a sensitivity of 80 .7 %, and an AUC of 0 .85 to predict PDAC[30].Furthermore, the model based solely on personal health data was able to divide individuals into low, medium, and high cancer risk. Identification of high-risk individuals who would benefit from tailored screening may increase the probability of detecting early PDAC. While logistic regression was used to develop risk prediction models in many previous studies, Muhammadet al[30] employed an ANN model based on personal health big data and produced the highest AUC in the prediction model of PDAC risk.

    Such prediction models using AI will be beneficial for clinicians to estimate the PDAC risk of their patients easily after inputting their data. These models can be combined into an electronic medical record system or be available on portable devices such as tablets and mobile phones. They may also be useful for primary care physicians to stratify individuals into various risk categories. By such PDAC risk stratification, higher-risk individuals can be referred to a diagnostic department for more intensive and tailored assessments. More data and testing will be required to refine the performance of the AI-based prediction model of PDAC in order to facilitate its application in the clinical setting. An AI-based prediction model using clinical variables is non-invasive, cost-effective, and easy for early diagnosis of PDAC. Using AI to recognize signs in early PDAC and precancerous lesions is one of the key strategies to improving survival.

    DETECTION OF EARLY PDAC BY BIOMARKERS USING AI

    It is highly desirable to identify an effective PDAC diagnostic biomarker. Currently,the most widely employed biomarker for early PDAC detection is CA19 -9 , however it is not an perfect because of its comparatively low level of specificity and sensitivity(70 % with a 5 % error rate, for diagnosis of PDAC)[31 ,32]. Several molecular elements such as CA19 -9 , CEA, DUPAN, and Span-1 have been employed as biomarkers for diagnosis of pancreatic tumors[33], but none of them are sufficiently specific and sensitive to clearly distinguish cancer from healthy or benign diseases. Therefore, a solid tool with sufficient specificity and sensitivity is required to enable early PDAC diagnosis. Zhanget al[34] designed a novel AI (support vector machine) method based on relative gene expression ranking within tissue samples using the microarray gene expression data and RNA-seq data collected from two databases, GEO and TCGA.Zhanget al[34] then identified a qualitative diagnostic signature comprising 9 gene pairs (16 genes), that could distinguish PDAC (using expression profiles from PDAC and adjacent normal tissues) patients from non-PDAC (pancreatitis and normal tissues) and was a useful biomarker for early detection of PDAC. Seven genes in the nine-gene-pair signature, namely CTSE, HOXB7 , LAMC2 , ONECUT1 , RRM2 ,SERPINB5 , and UBE2 C, had previously been known to be associated with PDAC.Thus, AI-based tissue biomarker analysis identified a multiple-gene expression signature for detection of early PDAC.

    MicroRNAs (miRNAs) have been proposed as promising biomarkers for diagnosis of PDAC[35]. miRNAs are a group of short non-coding RNA molecules with 19 -25 nucleotides that have been considered as candidate biomarkers for early cancer diagnosis and precise prognosis[36]. Recently, miRNA-used liquid biopsy has become a promising approach for early detection of cancers. Several miRNAs in plasma of PDAC patients are abundantly expressed, supporting that circulating miRNAs could be helpful for PDAC detection[37]. Ganepola et al[38] employed three circulating miRNAs (miR-22 , miR-642 b-3 p, and miR-885 -5 ) for detection of PDAC, and the AUC value was 0 .97 for discrimination of the PDAC cases. Liu et al[39] utilized a serum panel including miR-20 a, miR-21 , miR-24 , miR-25 , miR-99 a, miR-185 , and miR-191 for diagnosis of PDAC at different stages, and the AUC value was 0 .99 . Alizadeh Savarehet al[40] assessed the value of top miRNAs using a machine learning method (particle swarm optimization + ANN + neighborhood components analysis) to assist early diagnosis of PDAC. They identified a number of serum miRNAs that were significantly differentially expressed in 671 microarray PDAC expression profiles,using bioinformatics techniques Their final model comprised the most promising miRNAs (miR-92 a-2 -5 p, miR-125 b-3 p, miR-532 e5 p, miR-663 a, and miR-1469 ) with the high performance (accuracy, 0 .93 ; sensitivity, 0 .93 ; and specificity, 0 .92 ) in differentiation of PDAC from controls.

    Early detection of PDAC using tissue and/or blood biomarkers in conjunction with AI is an alternative approach to improving survival.

    DETECTION OF EARLY PDAC BY RADIOMICS

    Nowadays, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound, endoscopic ultrasound are the most popular imaging modalities for PDAC detection. However, these modalities are often employed in patients with symptoms,which results in delayed detection of PDACs in most cases. A promising application of AI technology is in the earlier detection of PDAC from radiological findings. CT is the most frequently used modality for the initial assessment of suspected PDAC, and its sensitivity of detection ranges from 76 %-96 %[41]. CT imaging can collect information about tumor location, size, and morphology. The pancreas is considerably different in size, shape, and location among the individuals and possesses only a very small part of the entire CT image, or about 1 .3 % of each CT image in a CT dataset[42]. Furthermore, a tumor shows high similarity to the surrounding tissues. Therefore, visual diagnosis demands doctors with enough clinical experience, because the quality of CT images varies between different CT scanners and operators, and pathological texture features are hard to distinguish. Actually, 19 % of patients with pancreatic cancer who underwent a review of submitted outside imaging and repeat imaging at a tertiary referral center received major changes in diagnosis and/or disease stage[43].

    The features of early PDAC can be delicate and retrospectively ascertained up to 34 mo before the diagnosis of PDAC[44]. In a tertiary medical center, 7 .1 % of PDACs were missed even by radiologist assessment. This fact emphasizes the limitations in the conventional CT approach for PDAC. Prognostic outcome in patients with PDACs considerably deteriorates when tumor size exceeds 2 cm[45], however tumors smaller than 2 cm are frequently invisible on CT images and so about 40 % of small PDACs are missed[46]. An AI-based diagnostic tool might minimize such oversight. Therefore,there is a growing need to develop AI-based algorithms for accurate pancreatic tumor detection. Although deep learning has been investigated for the diagnosis of pancreatic cystic neoplasms[47], neuroendocrine tumors[48] and segmentation of the pancreas[49 -52], the usefulness of AI in the detection of PDAC has not yet been widely explored. AI can analyze thousands of images on a pixel-by-pixel level and is not susceptible to mistakes due to human error. Another strength of AI is automatic diagnosis, which takes no more than approximately 20 s per case from inputting the original CT image to obtaining a diagnosis.

    Liuet al[53] reported that the AUC of an AI [convolutional neural network (CNN)]platform for CT-assisted diagnosis of PDAC was 0 .963 . Furthermore, the time of the CT-assisted diagnosis was 20 s/case, which is remarkably shorter than the duration required for diagnosis by radiologists, indicating AI has good clinical feasibility. In a deep learning (fully end-to-end deep learning) model for diagnosing pancreatic tumors, Siet al[42] reported that the average test time per case was 18 .6 s, compared with at least 8 min for manual reviewing. Thus, the AI diagnosis system was more efficient than the conventional diagnostic approach.

    Liuet al[54] showed that CNN-based analysis could precisely discriminate cases with and without PDAC in portal venous CT. The CNN-based analysis achieved an accuracy approaching 99 % and missed fewer tumors than did radiologists. In this study, CNN-based analysis provided higher sensitivity compared to radiologists(0 .983 vs 0 .929 , respectively)[54]. CNN missed three (1 .7 %) of 176 PDACs (1 .1 -1 .2 cm).Radiologists missed 12 (7 %) of 168 PDACs (1 .0 -3 .3 cm), of which 11 (92 %) were correctly classified by CNN. The sensitivity of CNN for tumors smaller than 2 cm was 92 .1 % in local test sets and 63 .1 % in an external (US) test set. Although the latter sensitivity for tumors smaller than 2 cm initially seemed unsatisfactory, DeWittet al[46] reported that the sensitivity of CT by radiologist assessment was 53 % for PDACs smaller than 2 .5 cm[46]. Consequently, the sensitivity of the CNN-based analysis was equivalent to radiologist assessment. The lower sensitivity of the CNN in the external test set compared with local test sets might be attributed to differences in patients'ethnicity and race, and protocols or scanners, between the training and external test sets, which could present greater challenges for small tumors. An important factor that affects the imaging features of the pancreas is fat content. Higher fat content decreases the density of the pancreas on CT images, and several studies reported marked differences in pancreatic fat content between ethnicities and races[55 ,56].

    Radiologists were given with important clinical information from the clinicians when they assessed the CT images, whereas the CNN was provided with no information except CT images. Therefore, the major utility of the CNN was to support radiologists in judging whether a lesion or suspicious area in the pancreas harbored pancreatic cancer. For example, patients present with obstructive jaundice which is a typical sign of pancreatic cancer in the pancreatic head. Nevertheless, the CT findings are negative or equivocal. In such a situation, occult pancreatic cancer should be highly suspected even if no apparent mass is noted on CT image, given that about 40 %of PDACs smaller than 2 cm are missed on CT image due to undefined borders with surrounding tissue[46 ,57].

    With the wide application of endoscopic ultrasonography (EUS) and EUS-fine needle aspiration (FNA) have become the important diagnostic modalities for PDAC;these modalities provide diagnostic accuracies up to 85 %, which are remarkably greater than the 50 % accuracy in CT-assisted diagnosis. The sensitivity of diagnosis of pancreatic tumors 3 cm in diameter was reported to be 93 % for EUS, which was greater than that of CT (53 %) and MRI (67 %)[58]. A meta-analysis revealed that CT and EUS were comparable in determining the resectability of PDAC, with high sensitivity and specificity[59].

    However, based on EUS for early diagnosis of PDAC, the experience and subjective factors affect on the accuracy, especially in the presence of chronic pancreatitis.Additionally, the availability of the EUS-FNA is restricted in community hospitals.Even when the EUS-FNA is utilized, the diagnosis can be also influenced by the operator's experience and the location of the needle insertion. In 2001 , Norton et al[60]reported the usefulness of neural network analysis of EUS images to distinguish between PDAC and chronic pancreatitis using 4 different image parameters. Although they provided a high sensitivity, the specificity was only 50 %. In 2008 , Das et al[61]applied techniques of digital image analysis to EUS images of the pancreas to develop a classification model that could differentiate PDAC from non-neoplastic tissue using ANN. The model accurately classified PDAC, with an AUC of 0 .93 and a 93 %sensitivity rate[61]. Digital analysis of EUS images is useful in differentiating PDAC from normal tissue and chronic inflammation. Given the possibility of real-time application, digital image analysis may become a helpful diagnostic modality in pancreatic diseases and may sometimes evade EUS-guided FNA. In another study,Zhanget al[62] differentiated between PDAC and normal tissue on EUS images.Regions of interest were selected from 216 images obtained from 153 cancer and 63 non-cancer patients, and a 97 .98 % sensitivity rate was obtained from the 29 features that were identified[62]. Zhu et al[63] conducted a computer-aided diagnosis utilizing EUS images of 262 PDAC and 126 chronic pancreatitis patients, from which 105 features were extracted. Sixteen of these features were selected for classification by a support vector machine and a 94 % sensitivity rate was obtained[63].

    EUS imaging is a common imaging method for diagnosing PDAC, and is often applied with FNA in distinguishing benign and malignant tumors. However, FNA is not available in all health centers. AI-assisted diagnosisviaEUS images should guide physicians toward more accurate and easier diagnosis.

    Collectively, AI can supplement radiologists to reduce miss rates, rather than replace them. The AI stands as a diagnostic tool to assist clinicians and radiologists in diagnosing PDAC. The application of AI in the diagnosis of PDAC has made substantial advances and is certainly improving.

    AI IN MOLECULAR/GENETIC SUBTYPE CLASSIFICATION

    Recent advances in biotechnology enable us to execute comprehensive genomic,transcriptomic, proteomic, and metabolomic analyses rapidly and cheaply. Such inclusive gene expression studies have uncovered subtypes of PDAC with biological and prognostic relevance. Collissonet al[9] proposed the categorization of PDACs into three subtypes: classical, quasi-mesenchymal (QM), and exocrine-like. The prognostic outcome of PDAC patients following operation and conventional medical treatment was notably better in the classical subtype than in patients with the QM subtype;patientss with the exocrine-like subtype displayed intermediate prognostic outcome between the two other subtypes[9]. Muckenhuber et al[64] subsequently reported that the most of PDAC can be categorized into two distinct subtypes based on transcriptome profiling and on immunohistochemical staining of cytokeratin-81 (KRT81 ) and hepatocyte nuclear factor-1 A (HNF1 a). The epithelial KRT81 -/HNF1 a-(double-negative) subtype (the so-called classical subtype) showed better survival and response to chemotherapy, notably to the FOLFIRINOX regimen, but not to a gemcitabine-based regimen. On the other hand, the epithelial KRT81 +/HNF1 asubtype (the so-called QM subtype) has worse OS. But, the QM subtype displays a better response to the gemcitabine-based regimen compared to the non-QM subtype[65]. These features encourage precision medicine based on individual molecular features.

    Recent developments in AI using medical image analysis such as radiomics reveal promising models of molecular phenotyping from imaging data. The radiomics approach can perform whole-tumor analytics without invasiveness. Kaissiset al[66 ,67]have reported on machine learning algorithms to preoperativelly predict molecular subtypes and survival risk in PDAC patients from MRI. However, the restricted availability of MRI data, overall decreased image quality, and the less-quantitative and unstandardized nature of MRI render obstacles to algorithm development and generalization. To reinfoce clinical application, Kaissiset al[68] extended their previous results to CT by training and validating an algorithm (random forest) capable of discriminating between the QM and the non-QM subtypes of PDAC. The advantages of CT comprise broad availability, fewer motion artifacts, and high standardization.Their retrospective study assessed baseline CT from 207 PDAC cases. By immunohistochemical staining for KRT81 and HNF1 a, the molecular subtype was determined as QMvsnon-QM. The random forest algorithm was used to predict the molecular subtype from the radiomic features. Then, the algorithm was applied to an independent cohort of histopathologically unclassifiable tumors. The classification algorithm achieved sensitivity, specificity, and AUC of 0 .84 , 0 .92 , and 0 .93 ,respectively. The median OS for predicted QM and non-QM tumors was 16 .1 and 20 .9 mo, respectively. The application of the algorithm to histopathologically unclassifiable tumors showed two groups with remarkably different survival (8 .9 and 39 .8 mo).Thus, the machine learning-based analysis of CT imaging provided the possibility of the prediction of molecular subtypes that is clinically relevant for prognostic outcome,permitting pre-operative stratification for precision medicine. This approach is encouraged by the fact that histopathological approachs are by default a significant underrepresentation of the tumor, since they are derived from a small sub-section of the tissue, and regions of differing molecular subtype are likely to coexist within the same tumor[69]. On the other hand, the radiomic approach enables whole-tumor assessment, providing better information required for precision therapy.

    Microsatellite instability (MSI) is a genomic property of cancers with defective DNA mismatch repair. Notably, MSI has been recognized as a biomarker for the favorable immune checkpoint blockade therapy response in cancer[70]. Most standard methods for examing MSI are based on DNA sequencing data and a few are based on mRNA expression data. Using RNA-Seq pan-cancer datasets for three cancer cohorts (colon,endometrial, and gastric cancers) from TCGA program, Liet al[19] established an algorithm called PreMSIm (Predicting MSI from mRNA) to predict MSI in cancer from the expression profiling of a 15 -gene panel. A benefit of mRNA-based over DNAbased MSI prediction algorithms is that mRNA data are closer to protein and phenotype than DNA data. Pathway analysis revealed that these genes were mainly involved in DNA damage repair (MLH1 and MSH4 ), gene expression (MLH1 ,HENMT1 , and RPL22 L1 ), cell cycle regulation (MLH1 , MSH4 , and HENMT1 ), and metabolism (NHLRC1 and RPL22 L1 ). Gene ontology analysis showed that these genes were involved in the biological processes of DNA repair (MLH1 , MSH4 , and RTF2 ),gene expression regulation (NHLRC1 and HENMT1 ), cell cycle (MLH1 , MSH4 ,RPL22 L1 , and RTF2 ), biogenesis (DDX27 , EPM2 AIP1 , NHLRC1 , and RNLS), metabolic process (HENMT1 , LYG1 , NHLRC1 , and SMAP1 ), and cell and organism development(SMAP1 , SHROOM4 , and TTC30 A). The PreMSIm algorithm provided high performance in predicting MSI using both RNA-Seq and microarray gene expression datasets[19]. Furthermore, PreMSIm showed superior or comparable performancevsother DNA- or mRNA-based methods. Liet al[19] comment that PreMSIm can be an alternative approach for identifying MSI. The introduction of machine learning algorithms such as this as a clinical decision support tool should be beneficial to predict molecular/genetic signatures that may help to stratify patients in clinical routines.

    AI IN RISK ASSESSMENT FOR PANCREATIC SURGERY

    In the pancreatic fields, the availability of AI in surgery is still very limited. An AIbased risk prediction model of postoperative complication has been reported[71 ,72].Postoperative pancreatic fistula (POPF) is a serious complication after pancreatoduodenectomy (PD). The fistula risk score (FRS), which consists of four variables —soft pancreas, small main pancreatic duct, high-risk pathology (PDAC or chronic pancreatitis), and massive intraoperative blood loss — is useful to predict clinically relevant POPF development after PD[73 ,74]. However, the score contains subjective factors related to surgeons. Therefore, an accurate and easy-to-use preoperative index is desired. Kambakambaet al[71] examined whether quantitative analysis of plain CT with five types of machine learning algorithms (k-nearest neighbors, sequential minimum optimization, multilayer perceptron, random forest, and C5 .0 ) could predict clinically relevant POPF in 110 patients from a single institution, and found that machine learning-based CT analysis provided an magnificent AUC of 0 .95 in predicting clinically relevant POPF[71]. Mu et al[72] tried to predict clinically relevant POPF after PD using a deep learning (CNN model) score derived from preoperative CT. The deep learning score offered significantly greater predictability compared to FRS in training (0 .85 vs 0 .78 in AUC, respectively), validation (0 .81 vs 0 .76 in AUC,respectively) and test (0 .89 vs 0 .73 in AUC, respectively) cohorts. In particular, in patients of intermediate risk (FRS 3 -6 ), the deep learning score achieved remarkably higher accuracy compared to FRS (test: 92 .1 % vs 65 .8 %, respectively). Interestingly, the deep learning score was independently associated with pancreatic fibrosis, diameter of main pancreatic duct and remnant volume in multivariate linear regression analysis.The automated scores reflected histomorphological features related to pancreatic duct,parenchymal fibrosis, and remnant pancreatic tissue volume. Thus, an AI model using preoperative CT represents a novel tool to predict clinically relevant POPF after PD,especially at intermediate risk levels. Such an AI system helps surgeons to optimize preoperative strategy.

    AI IN SURVIVAL PREDICTION AND RESPONSE TO CHEMOTHERAPY

    The potential of radiomics in prediction of clinically relevant conditions, such as expected OS or response to a specific therapy, has been reported in recent studies[75 ,76]: For instance, CT-derived radiomic features were useful to predict local disease control and OS in PDAC[75 ,76]. Entropy-related and cluster tendency features were described as predictive of OS in PDAC[76]. Zhang et al[77] proposed that a CNNbased survival model outperforms a Cox proportional hazard model-based radiomics pipeline in PDAC prognosis. This model provides a better fit for survival patterns based on CT images and overcomes the limitations of conventional survival models.Kaissiset al[66] reported that a machine learning algorithm (random forest) using MRI achieved 87 % sensitivity, 80 % specificity, and AUC 0 .9 for the prediction of above-vsbelow-median OS in the independent validation cohort. Alizadeh Savarehet al[40]have identified several circulating miRNAs as a diagnosis model in PDAC patients by analyzing microarray miRNA expression profiles from the Gene Expression Omnibus database. Three (hsa-mir-1469 , hsa-mir-663 a and hsa-mir-532 ) of five miRNAs with a high rank in the final model were comprehensively associated with the OS of patients with PDAC based on their up- or down-regulated expression patterns[40].

    Late diagnosis of PDAC can cause to lose the chance of surgical treatment and lead to a high mortality rate[78]. On the other hand, surgical treatments for PDAC can have a high morbidity and mortality rate. Therefore, the clinicians must weigh the potential survival advantage of the invasive treatment, the complications due to invasive treatment, and the impacts on the patient’s quality of life with and without treatment.

    Walczak and Velanovich[79] established ANN models that could accurately predict the 7 -mo survival of PDAC patients using 14 clinical variables including eight SF-36 domain values, both with and without surgical resection, at 91 % sensitivity and 38 %specificity. The ANN model to predict 7 -mo survival consisted of age, sex, the eight domains of quality of life measurements from the SF-36 , the stage of the cancer,whether or not a resection had taken place, if any adjuvant therapy had been given,and time in months since diagnosis. The quality of life domains from the SF-36 are bodily pain, vitality, physical functioning, social functioning, role-physical, roleemotional, general health, and mental health. Such an ANN model for predicting the survival of PDAC patients helps physicians and patients to reduce anticipated regret from treatment decisions including observation. This information may be useful for patients and surgeons in determining invasive treatment plans to minimize regret and improve the patients' quality of life.

    Neoadjuvant therapy may provide improved survival of PDAC patients; but,determining the efficacy is difficult. Watsonet al[80] hypothesized that a deep learning(CNN) model could predict the tumor response to neoadjuvant therapy using CT and CA19 -9 . A total of 81 cases were divided between partial responder (333 images) and non-responder (443 images). The model using only the deep learning model had an AUC of 0 .738 , whereas a hybrid model incorporating a decrease in CA19 -9 of 10 % in addition to the deep learning model had an AUC of 0 .785 . CA19 -9 reduction alone was not an effective predictor of the response to neoadjuvant therapy, with an AUC of 0 .564 . A deep learning model can predict the pathological response to neoadjuvant therapy for PDAC patients, and the model is amended with the incorporation of decreases in serum CA19 -9 . Abraham et al[81] investigated the clinical relevance of a machine learning-derived signature in predicting the responses from first-line oxaliplatin-based chemotherapy in PDAC and advanced colorectal cancer. The machine learning-derived signature was effective for metastatic colorectal cancer, but not for PDAC. AI has already been applied to match biological information with chemical properties of specific drugs to predict the response to these specific agents in cancers[82].

    In the near future, the combined analysis of clinical variables, less-invasive biological samples, and radiological features through machine learning should be able to simulate responses to chemotherapy and patient survival. On the other hand,radiological features and biological tissue can be variable in response to the treatment including chemotherapy and radiotherapy. In particular, PDAC has a high potential for acquired drug resistance. During sequential treatment, good communication and the accumulation of knowledge from various fields such as gastroenterology,radiology, oncology, computer science, and pathology must will be required to fight this deadly disease.

    Figure 2 Future perspectives in the management of pancreatic ductal adenocarcinoma by artificial intelligence. AI: Artificial intelligence;PDAC: Pancreatic ductal adenocarcinoma.

    LIMITATIONS AND FUTURE PERSPECTIVES

    A major limitation is the lack of adequate standardization. Universal and uniform protocols for data collection, data quality, storage, processing, reproduction, and analysis must be established. For instance, ANNs can be trained to appropriately categorize histologic slides of pancreatic biopsies. However, the trained ANNs may underperform, or not perform at all, when the prepared slides are fixed and stained in a different manner. Development of universal and uniform protocols during data and sample processing will be required for medical AI to be feasible. Further improvement of the technology is also essential for medical AI in clinical practice.

    AI in the medical field should become an indispensable tool to reduce human error.Because of human limitations, we cannot achieve zero errors. Furthermore, it is timeconsuming to train professional radiologists, gastroenterologists, oncologists, and pathologists. Combined work by experts from multiple fields will be needed to establish feasible medical AI systems in clinical practice. With further research, AI must have a great impact on the diagnosis and treatment of PDAC in near future.Ultimately, a sequential approach involving risk prediction, diagnosis, treatment, and survival prediction using IA will realize timely and consecutive precision medicine and lead to improved prognosis in PDAC (Figure 2 ). Dr. William Osler stated:“Medicine is a science of uncertainty and an art of probability.” This is still true in medical AI, which is also “a science of uncertainty and an art of probability.”However, the degree of uncertainty and probability will consistently shrink with the advance of AI technology and cooperation among various experts. While AI applications in PDAC are still in the early stage of development, further research must lead to great advances in screening, early diagnosis, and treatment.

    CONCLUSION

    Here we summarize the current advances of AI in PDAC. AI-based omics analyses are likely to be the next alternative approach to overcome this poor-prognostic disease by the discovery of biomarkers for early detection, molecular/genomic subtyping, and treatment guidance, and by the improved prediction of recurrence and survival. How to entirely utilize “big data” is a new challenge for physicians and researchers in the era of precision medicine. On the other hand, AI will not entirely act for doctors —human beings and machines working harmoniously together is the ideal state that results in excellent performance. Although AI data reveal that the diagnostic accuracy of deep learning models is better than that of radiologists, the aim in this field is to develop a helpful tool to aid radiologists in making effective and accurate diagnoses,not to be a replacement for doctors. To facilitate AI-based omics analyses, multidisciplinary collaboration between physicians, basic scientists, radiologists, statisticians, and engineers is mandatory. To further validate the clinical relevance of AI systems, next step is to conduct a prospective study based on multicenter clinical data. We believe that breakthroughs will soon emerge to fight this deadly disease using AI-navigated precision medicine.

    ponron亚洲| 久久国产乱子伦精品免费另类| 日本黄大片高清| 人妻夜夜爽99麻豆av| 欧美一区二区精品小视频在线| 国产午夜福利久久久久久| 精品不卡国产一区二区三区| 夜夜看夜夜爽夜夜摸| 国产精品1区2区在线观看.| 九九在线视频观看精品| 欧美三级亚洲精品| 全区人妻精品视频| 国产午夜福利久久久久久| 国产精品影院久久| 少妇被粗大猛烈的视频| 亚洲激情在线av| 亚洲激情在线av| 国产精品三级大全| 免费观看人在逋| 高清毛片免费观看视频网站| 成人性生交大片免费视频hd| 成人亚洲精品av一区二区| 真实男女啪啪啪动态图| 国产aⅴ精品一区二区三区波| 色视频www国产| 两个人的视频大全免费| 12—13女人毛片做爰片一| 日韩欧美 国产精品| 日韩成人在线观看一区二区三区| 国产一区二区三区视频了| 麻豆一二三区av精品| 日日摸夜夜添夜夜添av毛片 | 高清在线国产一区| 亚洲欧美日韩高清在线视频| 色综合婷婷激情| 久久精品国产亚洲av涩爱 | 有码 亚洲区| 我要搜黄色片| 一本久久中文字幕| 亚洲欧美日韩高清专用| 嫩草影院入口| 日本黄色视频三级网站网址| 日日夜夜操网爽| 免费在线观看日本一区| x7x7x7水蜜桃| 久久午夜福利片| 久久午夜亚洲精品久久| 久久久久性生活片| 99久国产av精品| 国产又黄又爽又无遮挡在线| 天堂av国产一区二区熟女人妻| 国内精品一区二区在线观看| 国产一区二区三区视频了| 日本与韩国留学比较| 男女做爰动态图高潮gif福利片| 88av欧美| 亚洲av熟女| 高清毛片免费观看视频网站| 成人av在线播放网站| 亚洲人与动物交配视频| 国产成人aa在线观看| 美女高潮的动态| 天堂av国产一区二区熟女人妻| 成人毛片a级毛片在线播放| 亚洲内射少妇av| 好男人在线观看高清免费视频| 国产精品伦人一区二区| 久9热在线精品视频| 少妇高潮的动态图| 亚洲经典国产精华液单 | 51午夜福利影视在线观看| 狠狠狠狠99中文字幕| 性插视频无遮挡在线免费观看| 国产精品嫩草影院av在线观看 | 日韩av在线大香蕉| 精品免费久久久久久久清纯| 观看美女的网站| a级毛片免费高清观看在线播放| 女生性感内裤真人,穿戴方法视频| 制服丝袜大香蕉在线| 日韩高清综合在线| 亚洲成a人片在线一区二区| 国产精品一区二区免费欧美| 亚洲无线观看免费| .国产精品久久| 中文字幕av成人在线电影| 免费av毛片视频| 国产高清有码在线观看视频| 午夜福利视频1000在线观看| 别揉我奶头~嗯~啊~动态视频| 老司机福利观看| 久久久久久久亚洲中文字幕 | 久久久久久大精品| 久久久久九九精品影院| 久久久久性生活片| 久久久精品大字幕| 国产黄片美女视频| 亚洲乱码一区二区免费版| 日韩精品青青久久久久久| 国产精品日韩av在线免费观看| 美女 人体艺术 gogo| 91在线观看av| www日本黄色视频网| 午夜亚洲福利在线播放| 亚洲国产精品久久男人天堂| 午夜福利在线观看免费完整高清在 | 精品熟女少妇八av免费久了| 色综合欧美亚洲国产小说| 欧美激情久久久久久爽电影| 亚洲自偷自拍三级| 日韩亚洲欧美综合| 国产熟女xx| 18禁黄网站禁片免费观看直播| 90打野战视频偷拍视频| 性插视频无遮挡在线免费观看| 99精品久久久久人妻精品| 久9热在线精品视频| 亚洲成人久久爱视频| 色尼玛亚洲综合影院| 9191精品国产免费久久| 亚洲电影在线观看av| 日本五十路高清| 九色成人免费人妻av| 成人午夜高清在线视频| 18禁黄网站禁片午夜丰满| 国产久久久一区二区三区| 亚洲午夜理论影院| 亚洲成人久久性| 国产伦精品一区二区三区视频9| 国产精品精品国产色婷婷| 国产亚洲精品久久久com| 亚洲第一电影网av| 激情在线观看视频在线高清| 亚洲精品色激情综合| 久99久视频精品免费| 亚洲一区二区三区不卡视频| 一进一出好大好爽视频| 51国产日韩欧美| 老司机深夜福利视频在线观看| 色噜噜av男人的天堂激情| 国产成人影院久久av| 中文字幕久久专区| 男女下面进入的视频免费午夜| 日韩高清综合在线| 直男gayav资源| 看黄色毛片网站| 内射极品少妇av片p| 在线观看免费视频日本深夜| 一区二区三区高清视频在线| 男女做爰动态图高潮gif福利片| 观看美女的网站| 非洲黑人性xxxx精品又粗又长| 亚洲av成人精品一区久久| 欧美不卡视频在线免费观看| 波多野结衣高清无吗| 亚洲熟妇中文字幕五十中出| 欧美xxxx黑人xx丫x性爽| 欧美3d第一页| 中文字幕高清在线视频| 熟女电影av网| 丰满的人妻完整版| 91在线精品国自产拍蜜月| 亚洲国产精品成人综合色| 免费看日本二区| 在线观看免费视频日本深夜| 嫩草影院精品99| 午夜福利成人在线免费观看| 欧美+亚洲+日韩+国产| 午夜亚洲福利在线播放| 成人一区二区视频在线观看| 精品国产三级普通话版| 别揉我奶头~嗯~啊~动态视频| 欧美乱色亚洲激情| 精品午夜福利在线看| 热99re8久久精品国产| 两性午夜刺激爽爽歪歪视频在线观看| www.999成人在线观看| 国产成人av教育| 亚洲欧美日韩东京热| 亚洲av免费在线观看| 无人区码免费观看不卡| 人妻制服诱惑在线中文字幕| 色综合站精品国产| 午夜久久久久精精品| 在线观看av片永久免费下载| 一区二区三区免费毛片| 国产伦在线观看视频一区| 我的女老师完整版在线观看| 成人鲁丝片一二三区免费| 在线观看免费视频日本深夜| 日本免费a在线| 日韩欧美国产在线观看| 每晚都被弄得嗷嗷叫到高潮| 色播亚洲综合网| 可以在线观看毛片的网站| 3wmmmm亚洲av在线观看| 国产中年淑女户外野战色| 欧美不卡视频在线免费观看| 舔av片在线| 精品人妻一区二区三区麻豆 | 亚洲欧美日韩高清在线视频| 男女做爰动态图高潮gif福利片| 一进一出抽搐动态| 麻豆成人av在线观看| 丰满乱子伦码专区| 99热这里只有是精品50| 午夜福利欧美成人| 午夜激情欧美在线| 日本黄色视频三级网站网址| 亚洲黑人精品在线| 国产精品不卡视频一区二区 | 国产欧美日韩精品一区二区| 国产不卡一卡二| 精品人妻熟女av久视频| 成人特级黄色片久久久久久久| 国产精品爽爽va在线观看网站| 亚洲第一电影网av| 亚洲国产精品sss在线观看| 一本一本综合久久| 三级男女做爰猛烈吃奶摸视频| a级毛片a级免费在线| 蜜桃久久精品国产亚洲av| 中文字幕av成人在线电影| 日本 欧美在线| 国产精品人妻久久久久久| 欧美午夜高清在线| 极品教师在线视频| 我的老师免费观看完整版| 性色av乱码一区二区三区2| 国产在线精品亚洲第一网站| 亚洲美女黄片视频| 美女 人体艺术 gogo| 国产精品亚洲一级av第二区| 嫩草影院新地址| 欧美潮喷喷水| 欧美黄色片欧美黄色片| 久久精品国产亚洲av天美| 成人国产一区最新在线观看| 青草久久国产| 少妇高潮的动态图| 国产精品爽爽va在线观看网站| 国产 一区 欧美 日韩| 国产三级在线视频| 三级毛片av免费| 一级黄色大片毛片| 岛国在线免费视频观看| 毛片女人毛片| 99国产精品一区二区三区| 中文字幕人成人乱码亚洲影| 亚洲熟妇熟女久久| 91久久精品电影网| 国产av不卡久久| 久久久色成人| 国产av麻豆久久久久久久| 97人妻精品一区二区三区麻豆| 午夜亚洲福利在线播放| 欧洲精品卡2卡3卡4卡5卡区| 免费av不卡在线播放| 一区福利在线观看| 观看美女的网站| 精品日产1卡2卡| 又黄又爽又免费观看的视频| 午夜福利欧美成人| 中国美女看黄片| 人妻丰满熟妇av一区二区三区| 国产爱豆传媒在线观看| 女生性感内裤真人,穿戴方法视频| 中文字幕精品亚洲无线码一区| 91狼人影院| 最新中文字幕久久久久| 日韩欧美精品免费久久 | 亚洲成人精品中文字幕电影| 啪啪无遮挡十八禁网站| 国产综合懂色| 国产高清视频在线播放一区| 变态另类丝袜制服| 成熟少妇高潮喷水视频| 色在线成人网| 日本黄色片子视频| 日韩精品青青久久久久久| 亚洲av免费高清在线观看| 日韩精品中文字幕看吧| 少妇裸体淫交视频免费看高清| 免费观看精品视频网站| 国产成年人精品一区二区| 精品日产1卡2卡| 免费看a级黄色片| 精品熟女少妇八av免费久了| 12—13女人毛片做爰片一| 性插视频无遮挡在线免费观看| 国产伦一二天堂av在线观看| 国产精品女同一区二区软件 | 国产精品久久久久久亚洲av鲁大| 日韩 亚洲 欧美在线| 小说图片视频综合网站| 久久久久国内视频| 小说图片视频综合网站| 在线观看午夜福利视频| 变态另类成人亚洲欧美熟女| 久久天躁狠狠躁夜夜2o2o| 欧美激情国产日韩精品一区| 国产精品自产拍在线观看55亚洲| 亚洲成av人片在线播放无| 国产av不卡久久| 真实男女啪啪啪动态图| 久久中文看片网| 国产成人啪精品午夜网站| 搡老岳熟女国产| xxxwww97欧美| 人人妻,人人澡人人爽秒播| 一级作爱视频免费观看| 身体一侧抽搐| 麻豆成人午夜福利视频| 身体一侧抽搐| 麻豆成人午夜福利视频| 亚洲第一区二区三区不卡| 午夜福利在线观看吧| 日韩精品中文字幕看吧| 亚洲黑人精品在线| 婷婷精品国产亚洲av| 男女之事视频高清在线观看| 天天一区二区日本电影三级| 性色av乱码一区二区三区2| 在线观看舔阴道视频| a级毛片a级免费在线| 国产av麻豆久久久久久久| 天堂动漫精品| 成人美女网站在线观看视频| 十八禁网站免费在线| 国产久久久一区二区三区| 日本免费一区二区三区高清不卡| 国产伦一二天堂av在线观看| 亚洲中文字幕日韩| 国产主播在线观看一区二区| 国产精品一区二区三区四区久久| 免费搜索国产男女视频| 看免费av毛片| 免费无遮挡裸体视频| 日韩免费av在线播放| 国产高清激情床上av| 性色av乱码一区二区三区2| 男人和女人高潮做爰伦理| 成年女人毛片免费观看观看9| 日韩欧美在线乱码| 国内少妇人妻偷人精品xxx网站| 精品乱码久久久久久99久播| 51国产日韩欧美| 婷婷亚洲欧美| www.999成人在线观看| 欧美黄色淫秽网站| 亚洲第一区二区三区不卡| 超碰av人人做人人爽久久| 老师上课跳d突然被开到最大视频 久久午夜综合久久蜜桃 | 国产激情偷乱视频一区二区| 18禁黄网站禁片免费观看直播| 成人无遮挡网站| 看黄色毛片网站| 国产精品久久久久久精品电影| 国产麻豆成人av免费视频| 变态另类成人亚洲欧美熟女| 欧美性猛交╳xxx乱大交人| 午夜久久久久精精品| 亚洲欧美日韩无卡精品| 国产欧美日韩一区二区精品| 成人高潮视频无遮挡免费网站| 五月玫瑰六月丁香| 日本黄色片子视频| 每晚都被弄得嗷嗷叫到高潮| 欧美在线一区亚洲| 欧美日本视频| 亚洲av成人av| 久久久久精品国产欧美久久久| 97人妻精品一区二区三区麻豆| 狂野欧美白嫩少妇大欣赏| 夜夜看夜夜爽夜夜摸| 色播亚洲综合网| 成人精品一区二区免费| 免费av毛片视频| 人妻久久中文字幕网| 日韩欧美精品v在线| 精品一区二区三区视频在线| 99久久九九国产精品国产免费| 久久久久久大精品| 老女人水多毛片| www日本黄色视频网| 老司机午夜十八禁免费视频| 一区二区三区高清视频在线| 日韩欧美精品免费久久 | 亚洲性夜色夜夜综合| 国产伦精品一区二区三区四那| 国产91精品成人一区二区三区| 免费看日本二区| 亚洲 国产 在线| 18美女黄网站色大片免费观看| 午夜日韩欧美国产| www.色视频.com| 成人性生交大片免费视频hd| 国产精品98久久久久久宅男小说| 少妇的逼好多水| 精品久久久久久成人av| 午夜福利在线在线| 国产黄a三级三级三级人| 又爽又黄无遮挡网站| 日韩免费av在线播放| 天天躁日日操中文字幕| 十八禁国产超污无遮挡网站| 亚洲成人中文字幕在线播放| 欧美激情在线99| 人妻久久中文字幕网| 欧美激情国产日韩精品一区| av中文乱码字幕在线| 国产黄a三级三级三级人| 国产真实乱freesex| 国产色婷婷99| 欧美一区二区精品小视频在线| 欧美性感艳星| 亚洲av电影不卡..在线观看| 国产极品精品免费视频能看的| 中文字幕熟女人妻在线| 久久人妻av系列| 男女下面进入的视频免费午夜| 99热这里只有是精品在线观看 | 亚洲五月天丁香| 一个人看视频在线观看www免费| 国产一区二区亚洲精品在线观看| 国产在视频线在精品| 日韩中字成人| 国产日本99.免费观看| 三级国产精品欧美在线观看| 18美女黄网站色大片免费观看| 成人永久免费在线观看视频| 麻豆国产97在线/欧美| 久久人妻av系列| 久久这里只有精品中国| 久久草成人影院| 91在线精品国自产拍蜜月| 91九色精品人成在线观看| 欧美一区二区国产精品久久精品| 免费在线观看日本一区| 亚洲综合色惰| 色哟哟·www| 非洲黑人性xxxx精品又粗又长| 身体一侧抽搐| 国产精品久久视频播放| 亚洲av中文字字幕乱码综合| 亚洲自偷自拍三级| 日本在线视频免费播放| 欧美在线黄色| 女人被狂操c到高潮| 国产精品久久久久久亚洲av鲁大| 好男人在线观看高清免费视频| 久久香蕉精品热| 亚洲国产精品成人综合色| 搞女人的毛片| or卡值多少钱| 人人妻人人看人人澡| 精品久久久久久久久av| av在线老鸭窝| 色吧在线观看| 又爽又黄a免费视频| 草草在线视频免费看| 亚洲av电影不卡..在线观看| 精品人妻视频免费看| 亚洲欧美激情综合另类| 亚洲 国产 在线| 午夜精品一区二区三区免费看| 男女下面进入的视频免费午夜| 成年女人毛片免费观看观看9| 男人舔奶头视频| 99精品久久久久人妻精品| 日本黄色视频三级网站网址| 午夜福利免费观看在线| 观看免费一级毛片| 久久久成人免费电影| 国产大屁股一区二区在线视频| 热99在线观看视频| 91麻豆av在线| 日韩中字成人| 国产精品亚洲av一区麻豆| 午夜福利在线在线| aaaaa片日本免费| 波多野结衣高清无吗| 日韩 亚洲 欧美在线| 12—13女人毛片做爰片一| 久久午夜亚洲精品久久| 成年女人看的毛片在线观看| 午夜福利在线观看吧| 一个人看的www免费观看视频| 亚洲av熟女| 日韩国内少妇激情av| 国产精品精品国产色婷婷| 免费av观看视频| 国产精品爽爽va在线观看网站| 天堂av国产一区二区熟女人妻| 亚洲内射少妇av| 亚洲在线自拍视频| 男女床上黄色一级片免费看| 九色国产91popny在线| 国产精品免费一区二区三区在线| 丰满人妻熟妇乱又伦精品不卡| av欧美777| 欧洲精品卡2卡3卡4卡5卡区| avwww免费| 国产久久久一区二区三区| 国产高清激情床上av| 亚洲美女搞黄在线观看 | 国产色爽女视频免费观看| 色吧在线观看| 真实男女啪啪啪动态图| 91麻豆精品激情在线观看国产| 午夜久久久久精精品| 免费一级毛片在线播放高清视频| av天堂在线播放| 精品熟女少妇八av免费久了| 一进一出抽搐gif免费好疼| 午夜福利免费观看在线| 少妇的逼水好多| 91麻豆精品激情在线观看国产| 夜夜夜夜夜久久久久| av在线蜜桃| 精品久久久久久久末码| 国产精品不卡视频一区二区 | bbb黄色大片| h日本视频在线播放| 亚洲性夜色夜夜综合| 亚洲午夜理论影院| 亚洲无线在线观看| 99精品在免费线老司机午夜| 国产一区二区在线av高清观看| 国产在线男女| a级毛片a级免费在线| 国产亚洲精品综合一区在线观看| 国产亚洲欧美在线一区二区| 日日摸夜夜添夜夜添小说| 久久精品综合一区二区三区| 丰满人妻熟妇乱又伦精品不卡| 欧美在线黄色| 色综合欧美亚洲国产小说| 3wmmmm亚洲av在线观看| 久久精品国产亚洲av天美| 免费高清视频大片| 99久久精品一区二区三区| 精品久久国产蜜桃| 欧美bdsm另类| 久久99热6这里只有精品| 欧美在线黄色| 国产在视频线在精品| 一二三四社区在线视频社区8| 中文字幕高清在线视频| 国产精品女同一区二区软件 | 毛片一级片免费看久久久久 | 日韩精品中文字幕看吧| 午夜亚洲福利在线播放| a级一级毛片免费在线观看| 久久精品影院6| 赤兔流量卡办理| 噜噜噜噜噜久久久久久91| 精品一区二区三区av网在线观看| 丁香六月欧美| 女生性感内裤真人,穿戴方法视频| 国产av麻豆久久久久久久| 国产欧美日韩精品亚洲av| 亚洲在线观看片| 国产精品自产拍在线观看55亚洲| 国产乱人伦免费视频| 日韩欧美免费精品| 亚洲,欧美,日韩| 色播亚洲综合网| 精品国产亚洲在线| 午夜精品久久久久久毛片777| 精品一区二区三区视频在线观看免费| 亚洲欧美日韩高清专用| 人妻夜夜爽99麻豆av| 亚洲欧美激情综合另类| 久久人人精品亚洲av| 午夜福利成人在线免费观看| 久久精品国产清高在天天线| 淫妇啪啪啪对白视频| 国产三级黄色录像| 亚洲午夜理论影院| 亚洲欧美日韩卡通动漫| 国产精品亚洲一级av第二区| 久久久国产成人免费| 国产野战对白在线观看| 久久精品国产亚洲av天美| 免费高清视频大片| 在线观看舔阴道视频| 啪啪无遮挡十八禁网站| 午夜福利在线观看免费完整高清在 | 老熟妇乱子伦视频在线观看| 午夜福利在线观看吧| 每晚都被弄得嗷嗷叫到高潮| 国产亚洲欧美98| 久久精品国产亚洲av香蕉五月| 久久国产精品人妻蜜桃| www.999成人在线观看| netflix在线观看网站| 丝袜美腿在线中文| 欧美日韩黄片免| 精品无人区乱码1区二区| 欧美bdsm另类| 亚洲精品粉嫩美女一区| 中文字幕高清在线视频| 91久久精品国产一区二区成人| 欧美日韩黄片免| 很黄的视频免费| 男人舔女人下体高潮全视频| 乱码一卡2卡4卡精品| 国产精品日韩av在线免费观看| 天天一区二区日本电影三级| 日韩高清综合在线| 日韩免费av在线播放| 美女高潮的动态| 久久久成人免费电影| 怎么达到女性高潮|